Autopsy report · NCT06113328

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

“Business Reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 8 months before it stopped.
• 169 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Non-segmental Vitiligo

Interventions

MK-6194; Placebo

Participants

169

Sites

68

Countries

Argentina, Australia, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Japan, Mexico, Netherlands and more

Trials that died the same way

• PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
  “Business reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.